Neurosterix Secures $105 Million for Schizophrenia Drug Development
By Adrian Cole

Neurosterix, a spin-out from Addex Therapeutics, has successfully raised $105 million in a Series B financing round to support the development of its lead schizophrenia drug, NTX-253. The announcement was made on November 11, 2026.
NTX-253, an orally administered, highly selective positive allosteric modulator (PAM) of the muscarinic M4 receptor, has completed Phase 1 clinical trials. The new funding will enable Neurosterix to advance NTX-253 into Phase 2 clinical development.
Though Addex Therapeutics did not participate in the funding round, it retains an 8.5% equity stake in Neurosterix, now valued at approximately $18.6 million.
In addition to NTX-253, the financing will also support the development of Neurosterix's broader pipeline, including NTX-819, a first-in-class mGlu7 negative allosteric modulator for mood and anxiety disorders, and NTX-529, a second differentiated M4 PAM targeting psychosis and mood disorders.
Neurosterix has also recruited key personnel from the team behind Bristol Myers Squibb’s muscarinic antipsychotic Cobenfy, highlighting strategic talent acquisitions to bolster its development efforts.